Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

 Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

Novartis Enters into a Four-Year Collaboration with Orionis Biosciences to Tackle Intractable Disease Targets

Shots:

  • Orionis to receive research funding, convertible notes, clinical milestones along with royalties while Novartis gets access to Orionis’ Allo-Glue technology platform for designing novel therapies like protein degraders across multiple therapeutic areas
  • The collaboration will combine Novartis’ expertise in drug discovery and development with Orionis’ innovative technologies for identifying and prioritizing new targets at a genome-wide scale
  • Allo-Glue molecules are the class of allosterically acting small molecules, which act by altering the function of intracellular proteins engaging in molecular interactions and modulating disease target proteins

Click here to­ read full press release/ article | Ref: Businesswire  | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post